
dCas9‑GFP‑VP64
$2,400.00 - $4,800.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: dC9GVP-500 (for 500pmol)
Cat. No.: dC9GVP-2500 (for 2500pmol)
Description
dCas9‑GFP‑VP64 is a multifunctional chimeric protein that integrates genomic targeting, real‑time visualization, and transcriptional activation. It consists of catalytically inactive Cas9 (dCas9), green fluorescent protein (GFP), and the VP64 transcriptional activation domain. The dCas9 component carries the D10A and N863A mutations, which completely abolish nuclease activity while preserving precise DNA‑binding capability directed by a single‑guide RNA (sgRNA).
GFP serves as a fluorescent reporter, providing a bright and stable signal that enables real‑time tracking of the protein’s subcellular localization, dynamic distribution, and target‑binding behavior. The VP64 domain—composed of four tandem copies of the herpes simplex virus VP16 activation motif—functions as a potent recruiter of transcriptional machinery.
When guided by a sequence‑specific sgRNA to a promoter region, dCas9‑GFP‑VP64 brings the VP64 activation module to the target locus. VP64 then recruits components of the transcription pre‑initiation complex, histone acetyltransferases, and other co‑activators, promoting RNA polymerase II assembly and transcription initiation. This results in robust upregulation of the target gene.
- Gene Transcription Activation: Upregulation of endogenous gene expression through targeted recruitment of transcriptional machinery.
- Gain‑of‑Function Screening: CRISPRa‑based genome‑wide screens to identify genes whose activation drives specific phenotypes.
- Cellular Reprogramming: Activation of pluripotency‑associated or lineage‑specific transcription factors to promote cell‑fate transitions.
- Epigenetic Studies: Investigating how targeted transcriptional activation influences chromatin accessibility and histone modifications.
- Gene Function Analysis: An alternative to cDNA overexpression for probing gene function in a more physiologically relevant context.
- Drug Target Validation: Activating candidate genes to evaluate their therapeutic potential and validate mechanism‑of‑action hypotheses.
SBS Genetech is recognized as one of the global major leading industry players in Gene Editing by third-party market researchers. For more details, please visit Global Gene Editing Service Market 2019 by Company, Regions, Type and Application, Forecast to 2024.
Related:
- Synthetic sgRNAs
- Cas12a Nuclease (Lyophilized)
- Cas12b Nuclease (Lyophilized)
- Cas13a Nuclease (Lyophilized)
- Cas14a1 Nuclease (Lyophilized)
- SpCas9 Nuclease (Lyophilized)
- SuCas12a2 Nuclease (Lyophilized)
- dCas9 NLS (Lyophilized)
- EiCsm6 (Lyophilized)
- LwaCas13a Nuclease (Lyophilized)
- BrCas12a Nuclease (Lyophilized)
- AsCas12a Nuclease (Lyophilized)
- Cas9 Nuclease (with NLS)
- Cas9 HF-NLS (SpCas9 HF-NLS)
- CRISPR-dCas9 Nuclease
- dCas9 NLS
- spCas9
- SpdCas9
- spCas9-NG
- SpRYCas9
- Cas9 Nickase (H840A) NLS
- Cas9 Nickase (D10A) NLS
- TsCas12a
- OsCas12a
- HkCas12a
- BoCas12a
- AsCas12a
- FnCas12a
- LbCas12a (Cpf1) Nuclease
- Enhanced LbaCas12a (Cpf1)
- Lb5Cas12a (Cpf1) Nuclease
- SuCas12a2 Nuclease
- AaCas12b
- AacCas12b
- AapCas12b
- BrCas12b
- LwCas13a
- LbuCas13a
- LtrCas13a (C2c2) Nuclease
- LwaCas13a (C2c2) Nuclease
- EiCsm6
- HheCas13a (C2c2)
- TccCas13a (C2c2)
- YmeCas12a (Cpf1)
- CmeCas12a (Cpf1)
- Enhanced LbCas12a
- PfAgo
- TtAgo
- T7 Endonuclease I










